Caremo Recognized as Jiangsu Potential Unicorn Enterprise for Third Straight Year

Recently, the New Quality Productivity Centre Of Jiangsu Province announced the 2025 assessment results for Jiangsu's Unicorn Enterprises and Gazelle Enterprises.

Caremo has once again been successfully recognized as a "Jiangsu Potential Unicorn Enterprise," based on its sustained innovation capability, technological strength, and high growth potential in the pharmaceutical R&D sector. This marks the third consecutive year, since 2023, that Caremo has received this honor, underscoring the continued high recognition of the company's development potential.

The data indicates that the vast majority of Unicorn and Potential Unicorn enterprises belong to fields related to the "1650" modern industrial system, with nearly one-quarter belonging to Jiangsu Province's "10+X" future industrial system.

The shortlisted enterprises this year primarily exhibit three key characteristics:

--- Unicorn and Potential Unicorn enterprises have become powerful new engines driving the development of new quality productive forces;

--- Gazelle Enterprises not only strongly drive industrial chain upgrading but also play a key role in stabilizing employment and optimizing the industrial structure;

--- Enterprises have further enhanced their independent innovation capability and core competitiveness, with their strategic role in accelerating the transformation of scientific and technological achievements into real productive forces and ensuring the security and stability of industrial chains becoming increasingly prominent.

The Unicorn Enterprises refer to innovative and entrepreneurial companies with a relatively short establishment history, a valuation exceeding USD 1 billion, and that are not yet publicly listed. "Potential Unicorn Enterprises," as the reserve force for Unicorns, are characterized by strong innovation capability, rapid growth, and significant market potential, serving as an important indicator for measuring regional innovation vitality and development momentum. Being selected as a "Jiangsu Potential Unicorn Enterprise" for three consecutive years is not only an honor but also solid confirmation of Caremo's long-term commitment to independent innovation and deep cultivation in the pharmaceutical R&D services field.

In future, Caremo will continue to deepen the innovation capacity of its technology platforms, persistently advance technological innovation and industrial collaboration, accelerate drug development timelines, reduce R&D costs, and improve R&D efficiency. The company aims to grow into a benchmark Unicorn Enterprise as soon as possible, contributing more "Caremo Strength" to the development of new quality productive forces in Jiangsu and to the advancement of China's pharmaceutical industry.